Associations between metabolic score for visceral fat and the risk of cardiovascular disease and all-cause mortality among populations with different glucose tolerance statuses
Copyright © 2023. Published by Elsevier B.V..
AIMS: To investigate the associations between metabolic score for visceral fat (METS-VF) and clinical outcomes among populations with different glucose tolerance statuses.
METHODS: We analysed 6827 participants aged ≥ 40 years with different glucose tolerance statuses from a cohort study. The associations between METS-VF and cardiovascular disease (CVD) events and all-cause mortality were assessed using Cox regression, restricted cubic spline and receiver operating characteristic curves.
RESULTS: During a follow-up of 5.00 years, there were 338 CVD events and 307 subjects experienced all-cause death. The METS-VF quartile (Quartile 4 versus 1) was significantly related to CVD events [adjusted HRs and 95% CIs: 5.75 (2.67-12.42), 2.80 (1.76-4.48), and 3.31 (1.28-8.54) for subjects with normal glucose tolerance, prediabetes and diabetes, respectively] and all-cause mortality [adjusted HRs and 95% CIs: 2.80 (1.43-5.49), 4.15 (2.45-7.01), and 4.03 (1.72-9.42), respectively]. Restricted cubic spline suggested a dose-response association of METS-VF with the risk of CVD events and all-cause mortality. The area under curve for CVD events and all-cause mortality was higher for METS-VF than for the other obesity and IR indexes in subjects with different glucose tolerance statuses.
CONCLUSIONS: The METS-VF was associated with an increased risk of CVD events and all-cause mortality and could be used as a predictive index of the risk of CVD events and all-cause mortality among populations with different glucose tolerance statuses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:203 |
|---|---|
| Enthalten in: |
Diabetes research and clinical practice - 203(2023) vom: 25. Sept., Seite 110842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Yurong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
Date Revised 08.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.diabres.2023.110842 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359950329 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359950329 | ||
| 003 | DE-627 | ||
| 005 | 20231226081951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabres.2023.110842 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359950329 | ||
| 035 | |a (NLM)37495020 | ||
| 035 | |a (PII)S0168-8227(23)00605-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Yurong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations between metabolic score for visceral fat and the risk of cardiovascular disease and all-cause mortality among populations with different glucose tolerance statuses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a AIMS: To investigate the associations between metabolic score for visceral fat (METS-VF) and clinical outcomes among populations with different glucose tolerance statuses | ||
| 520 | |a METHODS: We analysed 6827 participants aged ≥ 40 years with different glucose tolerance statuses from a cohort study. The associations between METS-VF and cardiovascular disease (CVD) events and all-cause mortality were assessed using Cox regression, restricted cubic spline and receiver operating characteristic curves | ||
| 520 | |a RESULTS: During a follow-up of 5.00 years, there were 338 CVD events and 307 subjects experienced all-cause death. The METS-VF quartile (Quartile 4 versus 1) was significantly related to CVD events [adjusted HRs and 95% CIs: 5.75 (2.67-12.42), 2.80 (1.76-4.48), and 3.31 (1.28-8.54) for subjects with normal glucose tolerance, prediabetes and diabetes, respectively] and all-cause mortality [adjusted HRs and 95% CIs: 2.80 (1.43-5.49), 4.15 (2.45-7.01), and 4.03 (1.72-9.42), respectively]. Restricted cubic spline suggested a dose-response association of METS-VF with the risk of CVD events and all-cause mortality. The area under curve for CVD events and all-cause mortality was higher for METS-VF than for the other obesity and IR indexes in subjects with different glucose tolerance statuses | ||
| 520 | |a CONCLUSIONS: The METS-VF was associated with an increased risk of CVD events and all-cause mortality and could be used as a predictive index of the risk of CVD events and all-cause mortality among populations with different glucose tolerance statuses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Glucose tolerance status | |
| 650 | 4 | |a Metabolic score for visceral fat | |
| 650 | 4 | |a Mortality | |
| 700 | 1 | |a Zou, Huajie |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yaming |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Peiqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Danpei |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Yuxi |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Beibei |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Limeng |e verfasserin |4 aut | |
| 700 | 1 | |a Kan, Ranran |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenjun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhelong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Junhui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Benping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xinrong |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Shuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xuefeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes research and clinical practice |d 1993 |g 203(2023) vom: 25. Sept., Seite 110842 |w (DE-627)NLM01260335X |x 1872-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:203 |g year:2023 |g day:25 |g month:09 |g pages:110842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabres.2023.110842 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 203 |j 2023 |b 25 |c 09 |h 110842 | ||